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Abstract
Cancer is the leading cause of natural death in the pediatric populations of developed countries, yet cure rates are
greater than 70% when a cancer is diagnosed in its early stages. Recent advances in magnetic resonance imaging
methods have markedly improved diagnostic and therapeutic approaches, while avoiding the risks of ionizing
radiation that are associated with most conventional radiological methods, such as computed tomography and
positron emission tomography/computed tomography. The advent of whole-body magnetic resonance imaging in
association with the development of metabolic- and function-based techniques has led to the use of whole-body
magnetic resonance imaging for the screening, diagnosis, staging, response assessment, and post-therapeutic
follow-up of children with solid sporadic tumours or those with related genetic syndromes. Here, the advantages,
techniques, indications, and limitations of whole-body magnetic resonance imaging in the management of
pediatric oncology patients are presented.
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Background
Cancer is currently the leading cause of natural death in
the pediatric populations of developed countries [1].
However, the cure rates for cancers are greater than 70%
in some cases when a cancer is diagnosed in its early
stages. To increase the cure rates for cancer patients,
diagnostic and therapeutic advances are needed. To se-
lect the most appropriate treatment for a child with can-
cer, the type, location, and staging of the tumour should
be completely assessed [2–4]. Ideally, imaging protocols
should be rapid, provide high quality images, have a low
radiation, and provide clinically significant information
[5–7]. In addition, every effort should be made to avoid
redundant examinations that do not provide additional
information relevant to therapeutic decision making [8].
There are many imaging modalities that are currently
used to characterise the extent of local and distant
disease. For example, ultrasonography, computed tom-
ography (CT), magnetic resonance imaging (MRI),
metaiodobenzylguanidine (MIBG) scans, and bone scin-
tigraphy (BS) are most frequently performed [8, 9]. How-
ever, modalities that deposit radiation, such as BS and
CT, should be used with caution in pediatric patients
due to the risk of complications, including the risk of
developing secondary malignancies.
Positron emission tomography/computed tomography
(PET/CT) has recently been used in children with can-
cer because it provides whole-body (WB) coverage and
information regarding the metabolic stage of tumours.
Regarding the latter, an intravenous injection of the
radiopharmaceutical, 18F-fluorodeoxyglucose (18F-FDG),
allows regions of abnormal glucose metabolism to be
detected with hybrid systems such as PET/CT and corre-
lated with possible morphological changes on anatomic
images [10, 11]. PET/CT also plays an important role in
tumour staging, in assessing response to treatment, and
can potentially predict treatment success in certain on-
cology settings [12]. Operational limitations of PET/CT
include its restricted availability to specialised centers in
many countries; the short half life of 18F which requires
prompt delivery and use [13]; and the radiation burden
to a patient.
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In contrast, MRI can provide exquisite anatomic de-
tail and functional information without radiation to
patients. In addition, technological advances, particu-
larly in the development of fast imaging sequences,
allow MRI to provide WB coverage in a reasonable
time frame [14, 15]. Thus, with the fusion of morpho-
logical sequences and functional techniques, such as
diffusion-weighted imaging (DWI) and WB morpho-
logical/functional mapping, relevant information re-
garding disease activity can be obtained [16, 17]. The
aim of this review is to discuss the advantages, tech-
niques, indications, and limitations of WB MRI in
evaluations of pediatric patients with cancer.
Main Text
Advantages of WB MRI
WB MRI provides a single examination of the entire
body without the use of ionizing radiation. In addition
to the excellent contrast and spatial resolution of WB
MRI, functional information is obtained which improves
the capacity of this method to differentiate normal
tissues from pathological tissues. MRI equipment is
often available at both large and small centers, thereby
facilitating the implementation of more advanced stud-
ies, such as MRI diffusion, perfusion, and WB studies
[18, 19]. Furthermore, a complete disease assessment in
the oncology setting, including detection of metastasis
sites, in a single examination helps to reduce the num-
ber of patient visits to an imaging service, thereby
reducing related costs [20].
Exposure to ionizing radiation is a major concern in
pediatric patients with cancer [7]. However, imaging
methods that use ionizing radiation sources, such as X-
ray, CT, BS, and PET/CT, are often routinely employed
[21, 22]. The risk of tumour development due to ioniz-
ing radiation exposure is related to the amount, inten-
sity, and accumulation of the applied radiation over an
individual’s life [23]. Newer CT scanners use iterative
image reconstruction which reduces radiation exposure,
although, exposure still occurs and repeated studies can
incur a significant radiation dose for a patient. This risk
increases when radiation exposure occurs at younger
ages, especially exposure during childhood. In a recent
study that examined the risks associated with the use of
imaging methods that employ ionizing radiation for
Fig. 1 A 15-year-old male patient follow up whole-body MRI
examination by bilateral retinoblastoma and osteosarcoma in right
femur, in the last exam, the T1-weighted image demonstrated a
lesion with low signal intensity in distal left femur. Histological
diagnosis of second osteosarcoma
Fig. 2 An 18-year-old female patient with a voluminous lesion in the left
hemi-pelvis (a, arrow) and histologically confirmed chondrosarcoma
underwent whole-body MRI with a coronal STIR sequence for staging. The
examination revealed involvement in the sacrum (a, arrow) and left ilium
(b, arrow) and the presence of soft-tissue components adjacent to marked
hyperintensity (c, arrow). Note the antalgic position, with slight body
deviation to the right. No other lesion suspicious of malignancy was noted
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diagnostic purposes, an estimated 29,000 new cancer
cases were found to be related to the number of CT
scans performed in the United States in 2007, with 15%
of the estimated cancers associated with scans that were
performed on patients younger than 18 years [24, 25].
An advantage of WB MRI is that it can be applied to at-
risk populations, including those that may be affected by
familial syndromes, to conduct cancer screenings. Ad-
vances in genetics have enabled the identification of
patients with hereditary syndromes related to the devel-
opment of neoplasms. The goal of performing WB MRI
for cancer screenings is to detect malignancies in their
early stages when the effectiveness of treatments and
cure rates are optimal [26, 27]. Ideally, screenings should
be applied to apparently healthy populations that are at
high risk for tumour development. Examples of inherited
syndromes that are associated with increased risks of
cancer include: multiple endocrine neoplasias I and II
(e.g., endocrine tumours), Von Hippel-Lindau syndrome
(e.g., renal carcinomas), familial adenomatous polyposis
(e.g., colorectal tumours), and Li-Fraumeni syndrome
(e.g., various types of tumours including sarcomas)
(Fig. 1) [28–31]. Correspondingly, a new screening
protocol that involves WB MRI has recently been pro-
posed for patients with Li-Fraumeni syndrome [32].
Magnetic resonance technique / protocol
To date, there is no overall consensus regarding a WB
MRI protocol for children. Typically, T1 and T2 imaging
are performed with free-breathing, suspended respir-
ation, or physiological motion control. It is also widely
accepted that short tau inversion recovery (STIR) se-
quences and diffusion add diagnostic value to WB MRI
examinations. Depending on a pediatric patient’s age
and size, a complete set of images are obtained in a sin-
gle acquisition (e.g., for infants), or in two or more seg-
mental acquisitions (e.g., for older children and
adolescents). The images are subsequently aligned using
specific software to enable visualization of the entire
body [20, 33]. WB MRI should be performed with high-
field (≥1.5 Tesla) equipment with surface and/or body
coils. Dedicated pediatric receiver coils are currently be-
ing introduced and will progressively have increased
availability. Patients should be examined from head to
toe in a supine position with their arms parallel to the
body and their legs together. Coronal acquisition, which
is more rapid than other approaches, is preferred, al-
though at least one sequence (e.g., diffusion) should be
acquired in the axial plane to compensate for the
Fig. 3 Whole-body MRI with a coronal STIR sequence in a 17-year-
old male patient with multiple lesions disseminated in the peritoneal
cavity and a histological diagnosis of mucinous adenocarcinoma of
high-grade colonic with abdominal implants
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limitations associated with coronal acquisition (e.g., for
the ribs, sternum, cranium, and spine) [34]. Sagittal
acquisition is helpful for evaluating the spine. However,
depending on the manufacturer, it is possible to perform
axial T1-weighted acquisitions without wasting time.
Moreover, synchronization of respiratory and cardiac
movements can be achieved with external gates to avoid
physiological motion artifacts [5, 33].
Conventional sequences, including T1- and T2-
weighted spin-echo sequences, are usually performed
without the administration of a paramagnetic contrast
medium. Malignant lesions are usually hypointense (low
signal intensity) on T1-weighted images (Fig. 1) and have
a high signal intensity on T2-weighted images [35].
The STIR sequence is highly sensitive for the detection
of pathologic lesions. Bone marrow lesions, including
marrow infiltration from lymphoma, metastases, and
tumour-related edema, exhibit high signal intensity on
STIR sequences (Figs. 2 and 3). Focal parenchymal le-
sions can be distinguished by their slightly different sig-
nal intensity in STIR sequences, while pathologic lymph
nodes cannot be differentiated from normal nodes on
the basis of signal intensity. The STIR technique also
cannot be used to differentiate benign conditions from
malignant neoplastic lesions. The latter limitation re-
stricts the application of STIR in WB MRI in onco-
logic patients after treatment, since therapy-induced
marrow changes, such as edema, necrosis, fibrosis, or
red marrow hyperplasia, cannot be differentiated from
viable tumours. However, STIR may be very useful in
staging pediatric tumours; although, additional clinical
experience and data are needed to determine its
efficacy [36, 37].
Diffusion-weighted MRI sequences are increasingly be-
ing employed for WB evaluations of patients with cancer
(Fig. 4). These sequences detect the random motion of
water molecules, also known as Brownian motion,
through biological tissues by detecting the protons in
the water molecules. The movement of the water mole-
cules causes a phasic dispersion of proton spin, thereby
resulting in signal loss due to diffusion sensitivity. The
signal intensity of an object of study is analyzed quanti-
tatively by calculating the absolute apparent diffusion
coefficient (ADC, in mm2/s) of the object relative to the dif-
fusion of water molecules in the proximal region [16, 38].
This qualitative and quantitative analysis is primarily influ-
enced by the presence of barriers that restrict the diffusion
of water molecules in their microenvironment, and this
produces imaging contrast between tissues. Thus, the signal
Fig. 4 A 9-year-old male patient with a histological diagnosis of
osteosarcoma in the left foot (arrow) underwent whole-body MRI
with diffusion sequences with three-dimensional reconstruction for
staging, which showed no other lesion site
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intensities and ADCs of different tissues are distinct as a re-
sult of their structural characteristics. The restricted diffu-
sion of water molecules that characterises malignant
tumours is potentially due to the increased cell density of
these tumours, thereby resulting in increased signal inten-
sity in DWI and reduced ADCs, both of which facilitate de-
tection of malignant lesions [16]. However, it should be
noted that particularly in children, a high signal in
DWI with body background suppression (DWIBS) can
be a normal finding in the bony pelvis and lumbar
spine. The different types of tissues with high cellu-
larity that are present within these bones contribute
to this high signal [39].
Currently, paramagnetic contrast agents can be used
in WB MRI examinations, although they are not always
indicated. It has been considered that the addition of
post-contrast sequences significantly increases examin-
ation time and that the behavioral characteristics of le-
sion enhancement cannot be examined in the arterial,
venous, and equilibrium phases simultaneously in WB
scans, especially when multiple organs are involved [40].
However, strategies have been developed to address
these limitations. For example, the Dixon technique
achieves a uniform separation of water and fat that is
resistant to large-field inhomogeneities compared to fat
suppression by chemical shift selective saturation
(CHESS) [41]. Furthermore, when properly imple-
mented, the Dixon technique can be used to acquire
either T1-weighted [42] or T2-weighted [43] images
within a single breath hold. These rapid Dixon se-
quences have been successfully incorporated into a WB
MRI protocol that is capable of providing multisequence
and multiplanar scans, including triphasic (arterial,
portal-venous, and equilibrium or delayed) contrast-
enhanced imaging of the liver, in approximately 1 h [44].
This Dixon-based WB MRI with multisequence and
multiplanar images are also complementary and facilitate
high-confidence reading, while multisequence and tri-
phasic contrast-enhanced abdominal imaging is very
useful for the detection and characterization of lesions
in the liver, an imaging examination that is more com-
monly performed in adult examinations [44, 45]. On the
other hand, however, it is important to consider that
administration of paramagnetic contrast agents are asso-
ciated with some risks, such as those for accidental
Fig. 5 Whole-body MRI with a coronal STIR sequence highlighting the cervical and thoracic regions of a17-year-old female patient with histologi-
cally confirmed non-Hodgkin lymphoma. a Multiple cervical lymphadenopathies in the supraclavicular and anterior mediastinal regions (arrows)
were detected at diagnosis. b A follow-up examination performed 15 days after chemotherapy showed that the lesions had disappeared
Fig. 6 Whole-body MRI with a coronal STIR sequence was
performed in a 3-year-old male patient with histologically confirmed
neuroblastoma. a and b The primary lesion appears as an extensive
retroperitoneal mass (white arrows), and multiple bone metastases
(black arrows) are present in the femoral
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puncture, allergic reaction, renal failure, and nephro-
genic systemic fibrosis [46]. Consequently, the prudent
use of gadolinium-based contrast agents to avoid or
minimise the risk of nephrogenic systemic fibrosis
cannot be overemphasised, as pediatric oncologic pa-
tients are more likely to have impaired renal function
secondary to anti-cancer therapy [47]. Pediatric pa-
tients should also be examined for hepatic lesions
following the administration of paramagnetic contrast
reagents, despite hepatic lesions being less frequent in
children than in adults.
For patients who are unable to receive gadolinium-
based contrast agents, ferumoxytol may be a useful MRI
contrast agent. Ferumoxytol is an ultrasmall superpara-
magnetic iron oxide (USPIO) that is comprised of iron
oxide particles surrounded by a carbohydrate coat. Ini-
tially, this agent was used to treat anemia in patients
with chronic renal failure [48]. However, more recently,
ferumoxytol has been investigated as an intravenous
contrast agent in MRI. The advantages of ferumoxytol
include its ability to be administered as a bolus
injection, allergic and idiosyncratic reactions with its
administration have been limited, and it is not
associated with a risk for nephrogenic systemic fibro-
sis [48, 49]. Femuroxytol also has a long intravascular
half-life of 14–15 h [50], and thus, can be used to
obtain different types of images. However, there is
currently a paucity of data available regarding its use
as a paramagnetic contrast agent.
Clinical indications
WB MRI can be applied for lesion detection/staging,
evaluation of treatment response, and follow-up and
screening of children with cancer predisposition
syndromes.
Lesion detection / staging
Clinical indications for WB MRI in pediatric patients
with cancer depend on the disease type and stage of
management. For several types of neoplasms, WB MRI
has been shown to be a valid alternative to CT, PET/CT,
and scintigraphic studies [20, 35, 47]. Many studies have
also shown that WB MRI can be applied at different
times during cancer management, including during the
screening, staging, response evaluation, and post-
therapeutic follow-up stages [5, 20].
The capacity for WB MRI to detect lesions depends
on several factors, including the anatomic site, size,
Fig. 7 Whole-body MRI with a coronal STIR sequence in a15-year-
old male patient with a lesion in the right distal femur and a
histological diagnosis of Ewing's sarcoma showed surrounding
soft-tissue components (arrow), but no other area of abnormal signal
intensity suggestive of malignancy
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histological type, and differentiation grade of the lesions
being examined. WB MRI has exhibited good diagnostic
accuracy in the staging of a variety of tumours, including
both lymphomas and solid tumours [51]. In fact, staging
of these neoplasms contributed to the development of
this examination technique [5, 51]. Currently, WB MRI
can detect lesions present in various anatomical sites,
such as the brain, cervical region, thoracic organs, abdo-
men, bone marrow, and musculoskeletal system. The
performance of WB MRI has also been shown to be
similar to that of PET/CT in the staging of different can-
cers, and superior to CT, BS, and scintigraphy with gal-
lium in evaluations of certain osseous and extra-osseous
metastases [35, 52, 53].
WB MRI enables a proper assessment of WB bone
marrow and the detection of compromised neoplastic
sites, including primary tumours and metastases arising
from diffusion [37]. However, since normal red marrow
impedes diffusion, this may confound disease detection
in younger children. Patients with melanoma and Lang-
erhans cell histiocytosis may be evaluated with WB
MRI. In fact, the sensitivity, specificity, and accuracy of
this method in these cases has been found to similar or
superior to those of other methods, including those
employing MIBG [20, 54]. WB MRI has also been
shown to perform well in the detection of bone metas-
tases, with a higher positive predictive value (94 vs.
76%, respectively) and greater sensitivity (99 vs. 26%, re-
spectively) observed compared with bone scintigraphy
[35]. The use of WB MRI is limited in the detection of
rib and skull lesions, although the use of respiratory
synchronization (triggering) has been shown to reduce
the occurrence of motion artifacts, thereby improving
the ability of WB MRI to evaluate these anatomic sites
[20, 55].
MRI provides different image contrasts that represent
specific tissue characteristics. This is important for eval-
uations of primary tumours and metastases in the brain.
Furthermore, if a lesion is detected in the brain or in an-
other part of the body during a WB MRI exam, then a
region-specific exam also needs to be conducted. Thus,
for patients with Li-Fraumeni syndrome who have an el-
evated risk of brain tumours, a brain-specific protocol
should be added to a WB MRI protocol.
Oncologic patients may undergo multiple MRI, thereby
receiving repeated administrations of a gadolinium-based
contrast agent. A high signal in the dentate nucleus and
globus pallidus on unenhanced T1-weighted images
should be cautiously evaluated in these patients, since the
signal observed may be a consequence of the number of
times that a gadolinium-based contrast material was
administered, and not due to the presence of pathologic
lesions [56, 57].
Currently, the most important clinical applications of
WB MRI in children include the staging of malignant
disease and screening for metastatic spread. These appli-
cations are particularly relevant in cases involving
lymphoma and solid tumours.
Lymphoma
Diagnostic imaging provides important information
regarding the staging and response assessment of lymph-
omas. Recently, a combination of CT and PET was ap-
plied to lymphoma staging and evaluations of treatment
response [58]. However, both PET and CT involve sub-
stantial radiation exposure, and children often undergo
Fig. 8 A 16-year-old female patient with primary mediastinal Hodgkin lymphoma (stage III-B) underwent whole-body MRI with STIR (a, c) and
diffusion (b, d) sequences. a and b Examinations performed for pre-therapeutic staging showed a voluminous anterior mediastinal lesion (arrows).
c and d Post-therapeutic imaging showed the presence of a residual mediastinal lesion with no sign of activity (arrows)
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several PET/CT examinations during a treatment course.
Thus, WB MRI represents a radiation-free alternative
for lymphoma staging and follow-up (Fig. 5). Further-
more, when WB MRI and CT were compared in their
capacity to provide staging of lymphoma, WB MRI was
able to provide disease staging, detect lymph nodes
greater than 1.2 cm (with sensitivity and specificity
values of 92.0 and 99.9%, respectively), and evaluate the
presence or absence of disease spread to bone marrow
[58]. In a study of eight children with lymphoma, WB
MRI with a coronal STIR sequence was also more sensi-
tive than conventional imaging (e.g., radiography, nu-
clear medicine studies - bone scintigraphy and gallium
scintigraphy - and CT) in detecting bone marrow in-
volvement in the initial stages of disease [15]. Following
treatment, however, residual and therapy-induced bone
marrow signal abnormalities could not be differentiated
from lymphomatous involvement [15].
Solid tumours
In various pediatric studies, the sensitivity of WB MRI
for the detection of distant metastases has been com-
pared with the sensitivities of radiography, CT, conven-
tional MRI, nuclear medicine studies, and PET/CT [53,
54, 59]. Additional studies have suggested that WB MRI
is a promising method for the detection of metastases in
patients with small cell tumours, and that WB MRI pro-
vides at least equivalent information to conventional
Fig. 9 A 20-year-old female patient with Li-Fraumeni syndrome in
whom multiple neoplasms had developed since childhood, including
lymphoma, soft-tissue sarcomas in the back and thigh, malignant
fibrous histiocytoma in the buttock, and adrenal carcinoma. Follow up
whole-body MRI examination since 2013, in the last the coronal STIR
sequence demonstrated the presence that new lung lesions and
kidney nodule. Histological diagnosis suggestive that metastasis of
pleomorphic undifferentiated sarcoma in lung and renal cell carcinoma
in kidney. Current Whole-body MRI with a coronal STIR sequence
demonstrate the presence of multiple lesions in lung (b, c white
arrows) and the kidney nodule (b, c black arrows), compared to
previous exam which demonstrated only the presence of simple renal
cyst (arrow), with no other change suggestive of malignancy (a)
Fig. 10 A 16-year-old male patient with histologically confirmed
osteosarcoma on the dorsum of the right foot underwent whole-body
MRI with a coronal STIR sequence for staging. a Note the lesion in the
right foot (arrow). b No skip metastasis or distant lesion was detected
Guimarães et al. Cancer Imaging  (2017) 17:6 Page 8 of 12
imaging studies [53, 59]. Neuroblastoma (Fig. 6), primi-
tive neuroectodermal tumour, rhabdomyosarcoma, and
Ewing’s sarcoma (Fig. 7) are small round-cell malignan-
cies that have been found to occur in the pediatric popu-
lation. For the detection of metastases to bone, most
investigators have reported a sensitivity of more than
97% for WB MRI, and WB MRI has consistently exhib-
ited a sensitivity comparable to, or greater than, that of
skeletal scintigraphy with technetium 99 m (99mTc)
medronate disodium [35, 53, 59].
Evaluation of treatment response and follow-up
WB MRI can be used to evaluate therapeutic response
in pediatric oncology patients [51, 60, 61], and the infor-
mation obtained can be used in combination with Re-
sponse Evaluation Criteria in Solid Tumors (RECIST)
[61]. For example, WB MRI can provide a morphological
assessment of target lesions by measuring their major
axes according to RECIST, while also providing a func-
tional evaluation of lesions with diffusion sequences.
Several studies have described the use of WB MRI to
identify partial or complete responses, including in-
creased absolute ADC, after the application of chemo-
or radiotherapy to brain tumours, liver tumours, and
sarcomas [62, 63]. Similar to CT and PET/CT, WB MRI
can also be useful in evaluating significant morpho-
logical and functional improvements in lymphomas
(Fig. 8), and these are often characterised by an inverse
correlation between the tendency toward increased ADC
and reduced tumour volume [35, 52]. Furthermore, WB
MRI can help distinguish between abnormal scarring
and recurrence after therapy [64], thereby enabling the
detection of any complications that are related or unre-
lated to disease or treatment.
Screening of children with cancer predisposition
syndromes
Cancer predisposition syndromes include a multitude of
cancers in which a mode of familial inheritance has been
clearly established, although a specific genetic defect
may not have been identified [65]. WB MRI has been
useful in the screenings of children with cancer predis-
position syndromes, and it also has the potential to pro-
vide a preclinical diagnosis of any associated tumours.
For example, at some institutions, WB MRI is performed
annually to screen for tumours in children with Li-
Fig. 11 Whole-body MRI was performed in a 6-year-old male patient with acute lymphoblastic leukemia for staging. a Diaphyseal and
metaphyseal lesions in the distal femoral and proximal tibial regions are represented by hyperintense signals in a coronal STIR sequence (arrows). b Signs of
bilateral renal infiltration by the underlying pathology (arrows) were observed. c A diffusion sequence demonstrated multiple hyperintense foci, consistent with
leukemic infiltration
Guimarães et al. Cancer Imaging  (2017) 17:6 Page 9 of 12
Fraumeni syndrome (Fig. 9). Li-Fraumeni syndrome is
an autosomal dominant hereditary syndrome that is
caused by a loss-of-function mutation in the TP53 gene
and affected individuals have a lifelong increased risk of
osteosarcoma (Fig. 10), soft-tissue sarcoma, leukemia
(Fig. 11), breast cancer, brain tumour, melanoma, and
adrenal cortical tumours [65]. Similarly, individuals with
hereditary retinoblastoma (RB) have a very high risk of
developing subsequent malignant neoplasms, with osteo-
sarcoma being the most common. When WB MRI screen-
ing tests were performed for survivors of hereditary RB,
the sensitivity and specificity of detecting subsequent ma-
lignant neoplasms was 66.7 and 92.1%, respectively [66].
Limitations
The use of WB MRI in pediatric oncological clinical
practice is limited in some cases. For example, standard
contraindications to conventional MRI, such as the pres-
ence of metallic body implants or history of claustropho-
bia, can also preclude the use of WB MRI. Due to the
examination time of WB MRI (which can range from
30 min to 1 h), the use of sedation or general anesthesia
is typically needed in a significant proportion of
pediatric patients, especially those who are young or un-
cooperative. Thus, the risks associated with these agents
must be considered. Immobilization during the examin-
ation is also essential for preventing motion artifacts
which can impair image acquisition and interpretation
of the findings. In addition, physiological artifacts related
to respiratory movements, heartbeat, and intestinal peri-
stalsis can impair image acquisition [67]. To minimise
the occurrence of these artifacts, multi-channel equip-
ment, body coils, and parallel imaging can be employed.
Furthermore, single-shot acquisition, the use of presa-
turation bands in the anterior body, and mechanisms of
synchronization with respiratory and cardiac movements
can reduce the time needed for an examination and
facilitate the acquisition of highquality images [67, 68].
Finally, the occurrence of false-positive results is another
limiting factor in the use of WB MRI. For example, in-
flammatory abnormalities, infections, and even benign
lesions such as simple cysts or vascular lesions have
been found to simulate malignant lesions [67].
Conclusion
Currently, WB MRI is able to provide total body
coverage, high tissue contrast, and good spatial reso-
lution without the use of radiation. Moreover, the abil-
ity to obtain relevant morphological and functional
information in a single examination represents a key
advantage of this method in the management of
pediatric oncology patients.
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imaging with body background suppression; MIBG: Metaiodobenzylguanidine;
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superparamagnetic iron oxide; WB: Whole body
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